FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W97852408> ?p ?o ?g. }

• W97852408 abstract "The formation of new blood vessels, i.e. angiogenesis, is an important phenomenon during normal development and wound repair, as well as during various pathological processes, such as tumor growth and metastasis. Specific growth factors regulate angiogenesis by modulating the different cellular functions of endothelial cells (EC), and periendothelial cells, such as pericytes (PC) and smooth muscle cells (SMC), which interact with ECs in a paracrine manner. ErbB receptors form a subgroup of transmembrane receptor tyrosine kinases that interact with growth factors of the epidermal growth factor (EGF) family. ErbB receptors regulate behaviour of a variety of normal as well as tumor cell types. Cancer drugs that target epidermal growth factor receptor (EGFR, ErbB1) or ErbB2 receptor have been approved for clinical use. It has been speculated that part of the antitumor activity of ErbB inhibitor compounds result from an antiangiogenic mechanism. The results presented here indicate a role for endothelial-derived EGF-like growth factors heparin binding EGF-like growth factor (HB-EGF) and neuregulin-1 (NRG-1) in the paracrine regulation of angiogenesis. HB-EGF, EGFR and ErbB2 are shown to mediate interaction between ECs and SMCs in vitro, and gefitinib, an inhibitor of EGFR kinase activity, suppresses recruitment of PCs/SMCs in vivo. NRG-1 is shown to regulate EC functions in vitro and angiogenesis in vivo by indirect mechanisms involving vascular endothelial growth factor-A (VEGF-A) and VEGF receptor-2 (VEGFR-2). Furthermore, EGFR activity is demonstrated to regulate recruitment of bone marrow-derived perivascular cells during tumor neovascularization in vivo. These results indicate that ErbB signaling is involved in the cellular processes of new blood vessel formation. This study gives new information about the role of ErbB ligands and receptors in angiogenesis and vasculogenesis and about the mechanisms by which ErbB inhibitor drugs such as gefitinib affect tumor growth." @default.
• W97852408 created "2016-06-24" @default.
• W97852408 creator A5088372544 @default.
• W97852408 date "2008-02-01" @default.
• W97852408 modified "2023-09-23" @default.
• W97852408 title "ErbB Ligands in Angiogenesis" @default.
• W97852408 cites W1232974837 @default.
• W97852408 cites W135877420 @default.
• W97852408 cites W1495287184 @default.
• W97852408 cites W1498071142 @default.
• W97852408 cites W1501383613 @default.
• W97852408 cites W1512987131 @default.
• W97852408 cites W1516410466 @default.
• W97852408 cites W1521352617 @default.
• W97852408 cites W1526670106 @default.
• W97852408 cites W1528666813 @default.
• W97852408 cites W1550364580 @default.
• W97852408 cites W1557061959 @default.
• W97852408 cites W1559595253 @default.
• W97852408 cites W1566059459 @default.
• W97852408 cites W1566258185 @default.
• W97852408 cites W1580361048 @default.
• W97852408 cites W1659692600 @default.
• W97852408 cites W1664817186 @default.
• W97852408 cites W1665419471 @default.
• W97852408 cites W1679229092 @default.
• W97852408 cites W1779286308 @default.
• W97852408 cites W1782450771 @default.
• W97852408 cites W179463710 @default.
• W97852408 cites W1890809256 @default.
• W97852408 cites W1915274548 @default.
• W97852408 cites W1933741179 @default.
• W97852408 cites W1935630572 @default.
• W97852408 cites W1945415917 @default.
• W97852408 cites W1963669837 @default.
• W97852408 cites W1963690717 @default.
• W97852408 cites W1964321121 @default.
• W97852408 cites W1965355187 @default.
• W97852408 cites W1967124443 @default.
• W97852408 cites W1970614272 @default.
• W97852408 cites W1972036696 @default.
• W97852408 cites W1972643490 @default.
• W97852408 cites W1973033337 @default.
• W97852408 cites W1973188134 @default.
• W97852408 cites W1973418567 @default.
• W97852408 cites W1973421681 @default.
• W97852408 cites W1974024530 @default.
• W97852408 cites W1974171881 @default.
• W97852408 cites W1974262159 @default.
• W97852408 cites W1974268455 @default.
• W97852408 cites W1974408216 @default.
• W97852408 cites W1976180996 @default.
• W97852408 cites W1976558852 @default.
• W97852408 cites W1977577504 @default.
• W97852408 cites W1977993125 @default.
• W97852408 cites W1979103623 @default.
• W97852408 cites W1979586311 @default.
• W97852408 cites W1980141913 @default.
• W97852408 cites W1980320450 @default.
• W97852408 cites W1982210988 @default.
• W97852408 cites W1982681624 @default.
• W97852408 cites W1983269054 @default.
• W97852408 cites W1983530651 @default.
• W97852408 cites W1985304386 @default.
• W97852408 cites W1985438884 @default.
• W97852408 cites W1985447634 @default.
• W97852408 cites W1985804036 @default.
• W97852408 cites W1986559037 @default.
• W97852408 cites W1988104771 @default.
• W97852408 cites W1988596206 @default.
• W97852408 cites W1990654868 @default.
• W97852408 cites W1991888662 @default.
• W97852408 cites W1991958278 @default.
• W97852408 cites W1992101966 @default.
• W97852408 cites W1993175314 @default.
• W97852408 cites W1993866602 @default.
• W97852408 cites W1994575090 @default.
• W97852408 cites W1995242599 @default.
• W97852408 cites W1995337883 @default.
• W97852408 cites W1996430165 @default.
• W97852408 cites W1996809093 @default.
• W97852408 cites W1999091296 @default.
• W97852408 cites W2000292756 @default.
• W97852408 cites W2001453148 @default.
• W97852408 cites W2002273560 @default.
• W97852408 cites W2002859032 @default.
• W97852408 cites W2004431186 @default.
• W97852408 cites W2009027924 @default.
• W97852408 cites W2009673528 @default.
• W97852408 cites W2011403734 @default.
• W97852408 cites W2011642803 @default.
• W97852408 cites W2012390831 @default.
• W97852408 cites W2012629036 @default.
• W97852408 cites W2013730676 @default.
• W97852408 cites W2014963592 @default.
• W97852408 cites W2015339197 @default.
• W97852408 cites W2015344488 @default.
• W97852408 cites W2015556441 @default.
• W97852408 cites W2016010426 @default.
• W97852408 cites W2016568386 @default.

• next